The United States Cardiovascular Drug Market displayed robust growth in assessment years. Cardiovascular disease is a fatal disease striking heart and related blood vessel disorders. They take on names as ischemic heart disease, dyslipedimia, stroke, thrombosis, atheroscelorosis, coronary artery diseases and likes. Cardiovascular diseases are diseases that strike the heart and block blood vessels. The various drugs available for treating cardiovascular diseases belong to a special class of medicines that target arrhythmia, myocardial infection and atherosclerosis. Anti-hypertensive drugs segment will hold dominant share of cardiovascular drugs market while anti-hyperlipidemcis segment slid up to top position to rake in market contribution in forecast period.
An enhanced population base that attracts high hospital visits on account of cardiovascular disease will demonstrate growth in hospital pharmacies segment. These disorders are linked to obesity, high cholesterol, smoking, excess alcohol and poor lifestyle. CVD is a major mortality source across the globe and more so with adults.
Cardiovascular diseases can be prevented with systematic and timely medication. The drugs ingested either enhance systolic rate of heart or act in enhancing supply of oxygen-rich blood to heart. Significant drugs prescribed for treatment cardiovascular diseases includes heparin, Coumadin, warfarin, sectral (acebutolol), Zebeta (bisoprolol), Lopressor, Toprol XL (metoprolol), Norvasc, Amlodipine, vascor and sular (nisoldipine).
Antihypersensitive drugs hold dominance amongst CVD market share in terms of growth revenue and this stage of growth is primarily attributed by presence of multibillion dollar drugs such as Diovan and Benicar. Thrombolytic brands hold smaller fraction of total share as compared to antihypersensitive drugs but are projected to be fast movers forcing pace of growth of cardiovascular drugs market by revenue growth. North America accounts for largest share of market because of significant awareness of heart diseases and furthermore heart diseases striking people in America. Segmentation of United States Cardiovascular Drug Market by drug class includes antihyperlipidemics, antihypertensive, anti-coagulants, antifibrinolytic, antiarryhtmic.
Segmentation of United States Cardiovascular Drug Market by distribution channel includes retail pharmacies, hospital pharmacies and online pharmacies. The key players in United States Cardiovascular Drug Market include Astra Zeneca, plc., Pfizer, Inc., Sanofi and Johnson and Johnson.
Geographically, this report splits the United States market into seven regions:
• The West
• The Middle Atlantic
• New England
• The South
• The Midwest
with sales (volume), revenue (value), market share and growth rate of Cardiovascular Drugs in these regions, from 2013 to 2025 (forecast).
United States Cardiovascular Drugs market competition by top manufacturers/players, with Cardiovascular Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
• Pfizer Inc
• Novartis AG
• Bristol-Myers Squibb
• Bayer AG
• Boehringer Ingelheim GmbH
• F. Hoffmann-La Roche
• Abbott Laboratories
• Gilead Sciences
• Johnson & Johnson
• Astellas Pharma
• Eli Lilly
• Otsuka Holdings
• Takeda Pharmaceutical
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
• Anti Hyperlipidemics
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
Research Support Specialist, USA